Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05610111 · ClinicalTrials.gov registry record · NA

Adaptive Biobehavioral Control (ABC) in a Closed-Loop System

A NA study, sponsored by Sue Brown.

Completed
Registry status
NA
Development phase
73
Enrollment target

NCT05610111: Completed NA study, sponsored by Sue Brown.

NCT05610111 is a NA study that has completed, run by Sue Brown. The registered enrollment target is 73 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05610111, a NA study, has completed, sponsored by Sue Brown.

COMPLETED
Registry status
NA
Development phase
73 participants
Enrollment target

Study Summary

This study is intended to test a Web-based Information Tool (WIT) software providing additional information regarding time in range, GMI, hypo- and hyperglycemia risks, variability tracker, daily glycemic profiles, and potential changes of insulin pump parameters, to users of a commercially available Closed-Loop Control (CLC) System (Control-IQ Technology).

Primary Outcome

The primary outcome for this study is CGM-measured percent time in range 70-180 mg/dL over the last 4-week periods on CLC+ABC versus 2 weeks of the current CLC system.

Interventions

  • DEVICE CLC + BAM
  • DEVICE CLC + ABC

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 2023-01-18
Est. Completion 2024-09-28
Phase NA
Sue Brown

6 total trials

What the finished NCT05610111 record still lists

NCT05610111 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 2 interventions - of which CLC + BAM is the first listed.

NCT05610111 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05610111 about?

NCT05610111 is a clinical study titled "Adaptive Biobehavioral Control (ABC) in a Closed-Loop System". This study is intended to test a Web-based Information Tool (WIT) software providing additional information regarding time in range, GMI, hypo- and hyperglycemia risks, variability tracker, daily glycemic profiles, and potential changes of insulin pump parameters, to users of a commercially availabl...

What is the current status of trial NCT05610111?

This trial is currently completed. It is a NA study. The enrollment target is 73 participants. The study started on 2023-01-18. Estimated completion is 2024-09-28.

What interventions are being tested in trial NCT05610111?

The interventions under investigation include: CLC + BAM (DEVICE), CLC + ABC (DEVICE).

Who is sponsoring clinical trial NCT05610111?

This trial is sponsored by Sue Brown, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05610111's enrollment target sits among peer trials

73 1089th of 2000 higher than 912 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03661307 · 73 participants · Phase 1

    Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

  • NCT05386108 · 73 participants · Phase 1

    Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

  • NCT05961592 · 73 participants · Phase 1

    R-2487 in Patients With Rheumatoid Arthritis

  • NCT06150664 · 73 participants · Phase 1

    A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05610111, the US trial registry maintained by the National Library of Medicine. NCT05610111 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.